Market Overview - The A-share market experienced fluctuations but closed higher, with the Shanghai Composite Index rising by 0.08%, the Shenzhen Component Index increasing by 0.7%, and the ChiNext Index up by 0.54% [1]. Precious Metals Sector - The precious metals sector led the market gains, with stocks such as Sichuan Gold (001337) and Zhaojin Gold (000506) hitting the daily limit [3][6]. - Notable price movements included Zhaojin Gold at 19.33, up 10.02%, and Sichuan Gold at 43.76, also up 10.01% [7]. Chip Industry - The chip industry saw significant activity, with stocks like Huada Technology (002185) and Longxin Technology reaching their daily limit [3]. Lithium Mining Sector - The lithium mining sector showed a rebound, with stocks such as Shengxin Lithium Energy (002240) and Dazhong Mining (001203) also hitting the daily limit [3]. Sports Industry - The sports industry stocks strengthened in the afternoon, with Jinling Sports (300651) rising over 14% and Shuhua Sports (605299) hitting the daily limit at 13.04 yuan per share, giving it a market value of 5.336 billion yuan [10][12]. ETF Trading Activity - There was a notable increase in trading volume for broad-based ETFs, with the Shanghai 50 ETF (510050) exceeding 15 billion yuan in trading volume, marking the highest level since July 2015 [5]. Gold Price Surge - Gold prices surged due to safe-haven demand and a weakening dollar, with London spot gold rising over 2.5% to surpass 4,880 USD per ounce, setting a new historical high [9].

Core Viewpoint - The investment landscape in 2026 is characterized by a clear trend towards allocating quality equity assets, driven by China's economic transition towards high-quality development and structural transformation [1] Group 1: Investment Strategies and Opportunities - The upcoming "Investment Good Season" strategy summit by Harvest Fund on January 23 will feature discussions with economists, investment professionals, and industry leaders to explore wealth creation and market opportunities [1][2] - The summit will address asset allocation strategies, including equity, fixed income, and multi-asset approaches, emphasizing the importance of a stable foundation and quality equity allocation in uncertain times [2] - Key speakers at the summit include senior executives from Harvest Fund who will share insights on strategy research, ETF investments, and multi-strategy approaches [2] Group 2: AI and Technology Investment - The AI sector is highlighted as a key focus for investment, with advancements in large model capabilities and increased capital expenditure driving discussions about the commercialization of AI applications [3] - A roundtable discussion will feature experts from Harvest Fund discussing the global AI industry's development and the implications of potential market bubbles [3] Group 3: Economic Policies and Consumer Demand - The optimization of supply and demand structures is expected to create new opportunities, with "de-involution" policies and "expanding domestic demand" being prioritized in economic strategies [4] - Experts from Harvest Fund will engage in dialogues about potential beneficiaries and investment rhythms in the context of macroeconomic trends [4][5] Group 4: Consumer Trends and Investment Insights - The summit will also focus on consumer investment trends, with discussions on various topics such as resource investments and dividend strategies, appealing to the interests of younger investors [6] - Insights will be shared on specific consumer trends, including the resurgence of tangible lifestyle investments and the growing popularity of gold and rare metals [6]

万孚生物介绍，公司自2018年起前瞻性地布局AI医疗领域，通过"并购+院端+C端"三位一体的策略，构 建了全面的AI医疗生态系统。公司通过战略投资、基金参股等方式，成功将赛维森医疗科技、生强科 技及医准智能三家在影像、病理和实验室诊断领域各具优势的企业纳入其生态圈。其中，赛维森医疗科 技于2025年2月获得了国内首张宫颈癌细胞数字病理图片辅助诊断软件三类医疗器械注册证，标志着其 在病理AI领域的领先地位。医准智能则在CT影像和超声影像AI检测软件方面表现卓越，目前已持有6张 三类证，其产品在多家医院实现商业化应用。生强科技则致力于打造病理数智化全链路解决方案，推动 医院病理科数字化工作流程的升级。这些战略投资不仅完善了万孚生物在多模态诊断领域的拼图，更形 成了强大的协同效应。 主业方面，万孚生物自身的海外业务同样展现出强劲的增长势头。记录表信息显示，公司基于发光、荧 光、胶体金三大免疫平台，在发展中国家与发达国家市场均取得重要突破。特别是在急诊场景和美国市 场的呼吸道三联检产品，预计将为2026年的海外业务带来显著增量。 公司表示，未来诊断将朝着多模态、多组学的方向发展，AI技术在其中的应用空间巨大。通过与生 ...

Group 1 - The core viewpoint of the report indicates that the overall opportunities in the equity market for 2026 outweigh the risks, with AI remaining the main theme of global technological innovation [1] - As of the end of Q4 2025, the stock position of the Silver Hua Xinyi fund was 88.55%, a decrease of 4.54 percentage points compared to the end of Q3 2025 [1] - The top ten holdings of the fund as of Q4 2025 include Tencent Holdings, Alibaba-W, SMIC, Meituan-W, Xiaomi Group-W, Focus Media, Shenzhou International, Yili Group, Luzhou Laojiao, and Wuliangye [1] Group 2 - The AI industry is experiencing explosive growth in capital expenditure globally, with domestic internet companies also showing rapid growth in capital spending [2] - The consumer sector is expected to lag in 2025, with consumers remaining cautious and price-sensitive, although there are opportunities in high-quality consumer stocks with attractive dividend yields [2] - The pharmaceutical sector experienced fluctuations in Q4, attributed to previously high market expectations and capital flowing to other popular sectors, but there is a long-term positive outlook for domestic innovative drugs and the CRO/CDMO segments [2]

Core Viewpoint - The rehabilitation industry is viewed as a "golden track" with significant growth potential, driven by brain-computer interface (BCI) technology, which is expected to reshape the industry landscape [1] Group 1: Technological Innovation - The company focuses on three cutting-edge areas: brain-computer interfaces, rehabilitation robots, and AI medical technology, with BCI technology accelerating commercialization [2] - A comprehensive product matrix for rehabilitation robots has been established, with plans to launch 5-6 new products by 2026, including various specialized robots [2][4] - The company has initiated a brain science laboratory and developed five technical platforms to enhance its BCI technology, achieving compatibility between EEG devices and rehabilitation equipment [4] Group 2: Research and Development Investment - The company plans to maintain R&D investment at over 20% of revenue for the next 3-5 years, with more than 30% allocated to frontier technology research [5] - In the first three quarters of 2025, R&D investment reached approximately 49.09 million yuan, a year-on-year increase of 27.67%, accounting for 27.58% of quarterly revenue [5] Group 3: Market Transformation - The company has partnered with over 600 leading hospitals to establish BCI rehabilitation treatment and clinical research centers, enhancing treatment precision and effectiveness [6] - The company is transitioning from passive to active rehabilitation models, leveraging BCI technology to empower various rehabilitation products [6] Group 4: International Expansion - The company is accelerating its international market strategy, with overseas sales expected to double in 2024 compared to 2023, aiming for international revenue to account for over 30% by 2030 [7] - The company is pursuing compliance certifications such as EU CE and US FDA to facilitate international market entry and is exploring partnerships and acquisitions to enhance its global presence [7] Group 5: Ecosystem Development - The company is focused on building a comprehensive rehabilitation ecosystem, emphasizing the integration of BCI technology into rehabilitation devices, which is seen as essential for future products [8] - The trend towards lightweight, portable, and home-based rehabilitation devices is expected to drive significant growth in the home rehabilitation market [8] Group 6: Industry Integration - The company plans to strengthen its supply chain for core components and aims to execute 3-5 mergers and acquisitions between 2026 and 2030 to integrate high-growth startups [9] - The company targets to establish chain rehabilitation hospitals featuring BCI and rehabilitation robots, with a goal of achieving over 20% of service revenue by 2030 [9]

Group 1: Technology Sector Performance - The technology sector experienced a broad rebound, with the semiconductor and computing power industries leading the gains [1][3] - Haiguang Information surged over 12%, reaching a historical high with a market capitalization of 664.16 billion yuan and a trading volume of 13.851 billion yuan, the highest in A-shares [1][2] - Other leading stocks in the semiconductor sector, such as Xin Yisheng, Tongfu Microelectronics, and Zhongke Shuguang, also saw significant increases in their trading volumes [3] Group 2: Semiconductor Industry Insights - The rise in semiconductor stocks is attributed to two main narratives: the anticipated price increase of CPUs and the surge in packaging and testing prices [5][7] - The demand for AI servers is expected to grow significantly, with global AI server shipments projected to increase by over 20% year-on-year by 2026, accounting for 17% of total server shipments [6] - The semiconductor packaging sector is facing price increases due to capacity shortages and rising costs of raw materials, such as precious metals [7] Group 3: Precious Metals and Energy Sector - The precious metals sector saw a notable increase, with stocks like Hunan Silver and Zhaojin Gold hitting their daily limits [8][10] - The price of spot gold surpassed $4,800 per ounce, marking a historical high and boosting market sentiment towards gold and related assets [11] - The lithium carbonate futures market also experienced a significant rise, driven by supply chain disruptions and renewed subsidies for electric vehicles in Germany [11]

农业银行发布的指引显示，信用卡用户可通过手机银行信用卡贴息专区、拨打信用卡客服热线主动签署 与查询信用卡贴息补充协议；也可在手机银行、客服等渠道办理账单分期时，按提示完成签署。 贴息支持范围扩大，信用卡账单分期业务也可以享受贴息了！ "信用卡账单分期财政贴息政策实施期为2026年1月1日至2026年12月31日，在2026年1月1日至政策发布 日之间已办理的信用卡账单分期可致电我行信用卡客服热线申请补贴息。"农业银行（601288）表示。 1月20日，财政部相关负责人在新闻发布会上表示，将信用卡账单分期业务纳入了贴息支持范围。截至 目前，多家银行已经响应该政策，明确贴息举措。此外，去年9月份开始实施的个人消费贷款财政贴息 政策实施期限将延长至2026年底，每名借款人可享受消费贷款和信用卡贴息的上限为3000元。 信用卡账单分期业务可贴息 实施期覆盖2026年全年 多家银行表示，信用卡账单分期业务财政贴息政策实施期为2026年全年。 农业银行表示，新办理的信用卡账单分期业务且于政策实施期内生成的各期账单，经该行识别其真实 性、合规性后，可按规定享受贴息。 "信用卡账单分期年贴息比例是1个百分点，而且最高不超过办 ...

6G第一阶段技术试验形成超300项关键技术储备，工业机器人产量同比增长28%，人形机器人产品超 330款，智能眼镜出货超178万副，智能算力规模达1590EFLOPS，人工智能核心产业规模预计突破1.2万 亿元……在1月21日国新办新闻发布会上，一组关于新兴产业和未来产业的最新数据，彰显经济发展的 强劲动能。 工业和信息化部副部长张云明介绍，回顾2025年工业和信息化发展，呈现"稳""进""新""活"四个特点。 2025年，我国规模以上工业增加值同比增长5.9%，制造业增加值占GDP比重保持稳定，制造业规模有 望连续16年保持全球第一。电信业务总量同比增长9.1%。工业和信息化领域对经济增长的贡献超四 成，有效发挥"压舱石"作用。 他表示，人工智能为工业经济增长注入强劲动力，并对2026年保持工业经济稳中向好态势充满信心。 AI核心产业规模预计突破1.2万亿元 人工智能应用不断拓展。目前，人工智能应用已覆盖钢铁、有色、电力、通信等重点行业，逐渐深入到 产品研发、质量检测、客户服务等重点环节。 工智能产业投资基金对人形机器人的支持力度，建设人形机器人开源社区，发布人形机器人与具身智能 综合标准化体系建设指南，促 ...

Group 1 - The company, Mindray Bio-Medical Electronics Co., Ltd., announced an investment of 30 million yuan as a limited partner in the Wuhan Zesen Juxin No. 2 Venture Capital Partnership, with a total fund size of 95 million yuan [2][3] - The company holds a 31.5789% stake in the fund but will not participate in specific investment decisions [2] - The fund primarily invests in equity of unlisted companies within the artificial intelligence infrastructure and terminal industry chain, focusing on sectors like optical interconnection and semiconductors [3] Group 2 - The collaboration with a professional investment institution aims to leverage its resources and management capabilities to enhance the company's investment layout and share in the growth dividends of emerging sectors [3] - The investment is fully funded by the company's own capital [3] - For the first three quarters of 2025, the company reported total operating revenue of 227 million yuan, reflecting a year-on-year growth of 0.53% [3]

中证智能财讯国泰海通（601211）1月21日公告，公司董事会审议通过议案，拟回购注销部分A股限制 性股票，总计8.17万股，回购资金总额为47.07万元，资金来源为公司自有资金。 本次回购涉及公司限制性股票激励计划中的3名预留授予激励对象。其中，2人因绩效考核未完全达标， 其当期未满足解除限售条件的1.00万股将按授予价格回购注销；1人因涉嫌违法犯罪，其尚未解除限售 的7.17万股将按授予价格与市场价格孰低的原则回购注销。回购价格为每股5.76元。 本次回购注销的股份数量约占公司总股本的0.000464%。回购注销完成后，公司该激励计划项下的A股 限制性股票将清零，同时另有291.69万股有限售条件股份将解除限售。 （文章来源：中国证券报·中证网） ...